Alkermes plc (ALKS) vs Neurocrine Biosciences, Inc. (NBIX)
- Alkermes plc ALKS 41.22 +2.79%
- Neurocrine Biosciences, Inc. NBIX 135.71 −0.91%
Alkermes plc and Neurocrine Biosciences, Inc. are both Drug Manufacturers Specialty & Generic companies. Neurocrine Biosciences, Inc. is the larger, with a market value of $13.9B against $6.7B — 2.1× the size. Neurocrine Biosciences, Inc. trades at the lower P/E: 19.2× against 102×. Neurocrine Biosciences, Inc. grew revenue faster over the last twelve months: 34.4% against 10.8%. Neurocrine Biosciences, Inc. has the higher net margin (20.9% vs 3.97%) and the higher return on invested capital (15.0% vs 2.76%). Across the 22 metrics below, Neurocrine Biosciences, Inc. leads on 20 and Alkermes plc on 2.
Valuation
Profitability
| Metric | ALKS | NBIX | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 84.56% | 97.94% | 53.94% |
| Operating margin | 7.03% | 23.56% | 0.00% |
| Net margin | 3.97% | 20.91% | 0.00% |
| Free cash flow margin | 13.35% | 25.80% | 0.00% |
| Return on equity | 3.85% | 22.09% | (0.40%) |
| Return on assets | 1.99% | 15.26% | (3.32%) |
| Return on invested capital | 2.76% | 15.04% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack